Jeff Su
Strategic Account Manager
Envirotainer

Jeff is a seasoned professional in multiple territories including business development, finance management, and cold chain management. He has been working with Envirotainer for over 8 years. He together with China team, have developed a vast partner network and achieved growth exponentially in China market.   Jeff has Master degree from Oklahoma State University.

George F. Gao
Director of the Chinese Center for Disease Control and Prevention
Academician of the Chinese Academy of Sciences

Member (academician) of Chinese Academy of Sciences, a fellow of The Third World Academy of Sciences (TWAS, also known as The World Academy of Sciences), a fellow of African Academy of Sciences (AAS), a foreign associate of National Academy of Sciences (NAS, elected in 2019) and so on. Director-General of Chinese Center for Disease Control and Prevention, Vice President of National Natural Science Foundation of China, Dean of Savaid Medical School, University of Chinese Academy of Sciences (UCAS), and Director and Professor of CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences.
Professor Gao obtained his PhD (DPhil) degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). His research interests include enveloped viruses and molecular immunology. His group research is mainly focusing on the enveloped virus entry and release, esp. influenza virus interspecies transmission (host jump), structure-based drug-design and structural immunology. He is also interested in virus ecology, esp. the relationship between influenza virus and migratory birds or live poultry markets and the bat-derived virus ecology and molecular biology. He has published lots of refereed papers (Including papers in Cell, Nature, Science, The Lancet, New England Journal of Medicine, Proceedings of the National Academy of Sciences USA etc.). His research has recently expanded on public health policy and global health strategy. Gao is a recipient of several international and national awards, including TWAS Medical Prize (2012), Nikkei Asian Prize (Japan 2014), Shulan Medical Sciences Award (2016), the Gamaleya Medal (Russia 2018), HKU Centennial Distinguished Chinese Scholar (2019) and the Qiu Shi Outstanding Scientist and Outstanding Scientific Research Team Awards (2019).

Tao Zhu
Chief Scientific Officer
Cansinotech

Tao ZHU is co-founder/CSO of CansinoBIO. Dr. Zhu was appointed as executive director on January 13, 2009 and has served as the chief scientific officer since January 2009. He is primarily responsible for leading  vaccine research and development for CanSinoBIO. In addition, Dr. Zhu also oversees  the management of regulatory and clinical affairs. Together with experts from the  Academy of Military Medical Sciences, Dr. Zhu led the development and pre-clinical research of the only available recombinant ebola vaccine in China, the production of which was approved by the CFDA. He also led the combinational vaccine project and PBPV project, both of which have been selected as one of the major science and technology projects in the National Twelfth Five-Year Plan for "Significant New Drug Creation" . His achievements also include the establishment of a conjugation technology platform and the development of a variety of vectors including CRM197, plus the process development, pre-clinical research and clinical application of several products, including MCV4, and the invention of seven patents in the PRC.

Hangwen Li
CEO
Stemirna Therapeutics

Dr. Hangwen Li has over 19 years' research experience related to cancer therapy and has published more than 20 articles and publications. Dr. Li has been awarded the doctorate fellowship and over 1 million U.S. dollars in research grant by the United States Department of Defense. Dr. Li founded Stemirna Therapeutics, Ltd. in Shanghai in May 2016, striving to create the first mRNA-based drug platform in China. The first product, mRNA-based personalized cancer vaccine, has reached pre-IND investigator-initiated trials in China. Dr. Hangwen Li received his Ph.D. degree in tumor biology from the University of Texas MD Anderson Cancer Center.

Ke Wu
CEO
BravoVax

Dr. Wu Ke is the Founder and CEO of BravoVax. He has more than 30 years of experiences in biopharm industry and had successfully developed 7 products being approved by CFDA and marketed in China. He also has 20+ granted patents from China or PCT.

He was Executive President of Shanghai Zerun Biotechnology, in charge of management of QA/QC, Manufacture, R&D, Engineering and Maintenance, Regulatory Affairs, Marketing, also extensively experienced in business development, technology transfer, etc. Prior to start Zerun, he was Director of R&D in Wuhan Institute of Biological Products, China National Biotec Group (CNBG), in charge of development of new vaccines and blood products.

He holds a PhD degree in Immunology, also alumnus of both China Europe International Business School (CEIBS) and Cheung Kong Graduate School of Business (CKGSB). He is a Specially-appointed Professor by Hubei Provincial Government.

Qihan Li
Director, Research Institute
Institute of Medical Biology, Chinese Academy of Medical Sciences

Dong Yu
Director of Preclinical Research, Director of Antibody Identification and Molecular Biology
GSK Vaccines

Ms. Wendy Huang
Assistant to General Manager
Head of Business Development, Head of PMO
Xiamen Innovax Biotech Co., Ltd.
Board Member,
Developing Country Vaccine Manufacturing Network (DCVMN)
Master of Science (2010) in Biochemistry and Molecular Biology,
Institute of Biochemistry and Cell Biology, SIBS, CAS
Bachelor of Engneering (2007) in Bioengineering, South China University of Technology

Ms. Wendy Huang joined Xiamen Innovax Biotech Co., Ltd. in 2010. With 10 years' experiences in vaccine industry, Wendy Huang is the key person in International collaboration network building, and contribute a lot in International business. Representing Innovax, she has been actively communicating and working with WHO, Unicef, Gavi, BMGF, PATH and DCVMN. She is familiar with vaccine lifecycle strategic planning, programme management, vaccine WHO prequalification, business development, and vaccine registration, etc. She has participated in all stages of HPV vaccine development, and is leading the WHO prequalification programme. As the key member, she has participated the business negotiation with GSK for HPV collaboration and is continue involved as programmed lead. In 2019, she was elected as Board member of Developing Country Vaccine Manufacturing Network (DCVMN).

Hang Yu
CEO
RNACure

Co-founder and CEO of RNACure. He graduated with a bachelor degree from Chu Kochen Honors College of Zhejiang University. In 2008 he received a master's degree in artificial intelligence from University of Florida. Then he founded APExBio Technology in Houston, TX in 2012. He received his MBA degree from Georgia State University in the same year. In 2019, he co-founded RNACure in Shanghai, focusing on the development of mRNA therapeutics.

Jiasheng Song
Founder
Zhejiang Difference biological Technology Co, Ltd

Dr. Jiasheng Song is the Founder of Zhejiang Difference biological Technology Co, Ltd. He received his Ph.D. from Chinese Academy of Agricultural Sciences in 2010. He performed his postdoc research in UW-Madison（Yoshihiro Kawaoka lab ), UPMC and Emory University during 2010-2016.Dr Song is strong in molecular virology and the development of genetic engineering vaccines. Currently, there are two vaccine products that is in the process of industrialization.(1) A novel DIVA influenza vaccine ; (2)A recombinant NDV vector Covid-19 vaccine. Over the past years, he deeply involved in several national and international key projects including Global Health Grant (Number OPPGH5383, Bill & Melinda Gates Foundation, "High-throughput analysis of avian influenza variants for pandemic potential") and the National Basic Research Program of China (973 Program).
Currently, Dr. Song takes charge of the project "Hangzhou Hi-Tech Zone 5050 Plan"(the title is Development and implementation of a novel DIVA influenza vaccine ). 3 National invention patents have been licensed and 9 International patents have been applied.

Aimin Hui
CSO
Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

President of Global R&D, CMO, and Chair of the Scientific Committee of Fosun Pharma；Director of Shanghai Key Laboratory of Stem Cell Therapy; Former global Vice-President of Clinical Development Oncology at Sanofi
Dr. Hui has 30 years of experiences in cancer treatment and innovative drug development in world's top medical centers and pharmaceutical companies. He has led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. He has recently led the deal of the joint development of an mRNA vaccine against COVID-19 BNT162 between BioNTech and Fosun Pharma and the execution of the program.
Dr. Hui has published more than 80 peer-reviewed articles on top scientific journals including The New England Journal of Medicine, The Lancet and Cancer Cell. He served as the Deputy Director of the Academic Committee of the 5th Chinese Conference on Oncology.
In 1990s, he conducted research in clinical oncology and molecular biology at National Cancer Center Japan, University of Tokyo Hospital, and was recognized as one of the international leaders in the field of molecular biology of liver cancer.
Since 2000, Dr. Hui has dedicated in anti-cancer drug research and development at National Cancer Institute (NCI), GE Healthcare, Takeda, Sanofi and Fosun Pharma. At Takeda, he led Ixazomib (the first oral proteasome inhibitor) global clinical development and registration as Global Clinical Lead and Global Submission Head, which took only 6 years from FIH to FDA full approval, and just 4 months from NDA submission to approval. He also created a new model of "a global pivotal trial with a China continuation cohort" for the first time in 2013, which significantly accelerated Izaxomib's approval in China. Ixazomib is now a strong generator of Takeda's revenue. At Sanofi, he led the global clinical & registration strategy and clinical trial design of the anti-CD38 antibody Isatuximab, which has been approved by FDA. He also led clinical development and registration of multiple novel drugs in China including Ixazomib, Bendamustin, Avatrombopag et al.

Norman Li
Chairman & President
Tianjin Ringpu Bio-Technology Co.,Ltd.

Li Shoujun, Male, born in 1963, Han nationality, Communist Party member, Doctor, researcher, Special Post expert of the State Council. In 1998 led the team to set up the Tianjin Ruipu Biotechnology Co. , Ltd. , specializing in biological vaccines, pharmaceutical raw materials, pharmaceutical preparations, rapid diagnostic kits and feed additives R & D, Production and sales; In 2010, it became the first gem company to specialize in Veterinary Medicine (Stock Code: 300119) .

He is currently the master's tutor of Agricultural University of Hebei, Inner Mongolia Agricultural University and Tianjin Agricultural College. He has presided over 17 science and technology projects at the national and provincial levels, and has won one national second-class award for scientific and technological progress and one first-class award for scientific and technological progress of Tianjin, tianjin Science and Technology Progress second-class Award 1, Other 9 awards; 12 granted patents, published in core academic journals published 14 research papers, published 2 monographs. He is Vice President of China Veterinary Medicine Association, Vice President of China Animal Husbandry Veterinary Medicine Association, President of Tianjin Animal Health Products Association, executive president of Tianjin Small and Medium Enterprises Association, President of Port of Tianjin Free Trade Zone Airport Enterprise Association. In 2010, as the director-general and initiator, she set up the only strategic alliance for technological innovation of Veterinary Chemicals Industry (SAVP) , which was recognized by the Industry Ministry of Science and Technology of the People's Republic of China. On the basis of this, she set up the strategic alliance for technological innovation of agricultural and animal husbandry industry of Tianjin, and promoted the gathering of domestic resources for innovation of veterinary drugs to Tianjin.
In 2015, Zhongchuang space was set up to incubate the biomedical industry, and two specialized funds including seed Fund and Strategic Emerging Industry Development Fund were set up, incubation, investment and industrial distribution around new veterinary drugs, pharmaceuticals, medical devices and the Agricultural Internet. Investment of the Ruipai pet hospital chain, currently controlling more than 200 pet hospitals, Goldman Sachs US $200 million strategic investment. With years of entrepreneurial experience and Industry Influence, he was selected in 2008 as one of the National Heroes of animal husbandry in the 30 years of reform and opening-up, and in 2009 as one of the most creative Chinese business leaders in the asia-pacific region. He was awarded the New China Animal Husbandry and Veterinary Science and Technology Contribution Award for 60 years, in 2010, he was selected as a leading figure in China's animal husbandry industry. In 2014, he was selected as the 3rd advanced worker in China's animal husbandry industry and was named the first batch of "outstanding entrepreneurs of Tianjin" in Tianjin, in 2016, he was selected as "science and technology innovation and entrepreneurship" under the Tianjin Innovation Talent Promotion Program, and in 2017, he was selected as "national science and Technology Innovation and entrepreneurship" under the Ministry of Science and Technology of the People's Republic of China, in 2018, he was selected as one of the "10,000 persons project" and "the first group of Science, technology, innovation and entrepreneurship tutors" of the Ministry of Science and Technology of the People's Republic of China.

Haifa Zheng
CEO &GM
Beijing Minhai Biological Technology Co.,Ltd.

Haifa Zheng, male, born on October 4, 1964, Chinese nationality, holds a bachelor's degree in animal medicine from Jilin Agricultural University and a master's degree in agriculture from the Graduate School of the Chinese Academy of Agricultural Sciences.He is currently the general manager of Beijing Minhai Biotechnology Co., Ltd., vice chairman and chief scientist of Shenzhen Kangtai Biological Products Co., Ltd., review expert of national 863 project and major new drug creation technology, and member of the National Pharmacopoeia Committee.
He is a member of the Standing Committee of the CPPCC in Daxing District, Beijing, andadjunct professor of the Third Military Medical University of the Chinese People's Liberation Army, Beijing Normal University, Changchun University of Science and Technology, Beijing University of Technology and so on.
He is also the member of Standing Committee of Biological Products Branch of Chinese Preventive Medical Association, Committee of Microbiology and Immunology Branch of Chinese Medical Association, Vaccine Committee of China Medical Biotechnology Association, Biological Products Supervision and Management Research Committeeof CSDR, Biological Medicine and Quality Research Committee of Chinese Pharmaceutical Association.
He led the research and development of the rabies vaccine (Vero cell), SARS vaccine, oral rabies vaccine, fox encephalitis vaccine, DTaP-Hib, Hib, measles and rubella combined vaccine (live), and Covid-19 inactivated vaccine.He participated in the research and development of 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, DTcP-Hib-sIPV, 5-valent Rotavirus vaccine (Vero cell), hepatitis A inactivated vaccine. With 30 years of experience in the pharmaceutical industry, he has won 10 national, provincial and ministerial awards, and has published more than 60 papers.

Wang Ying
Senior Clinical Operation Group Lead
Pfizer(China) R&D , Clinical Trial Management

In 2002, Wang Ying graduated from the discipline of Clinical Medicine of Capital Medical University and obtained a master's degree in Neurobiology in 2006. Fifteen years working experiences in the pharmaceutical industry. She once worked at the CHGB, Double Crane Pharmaceuticals, Novartis Vaccines, and Takeda. She joined Pfizer in 2010, is now the Senior Clinical Operation Group Lead for Vaccine & Internal Medicine areas. She has participated in different TAs and different stages of clinical development of innovative drugs, accumulated rich experience in clinical trial management.

Tongli Yao
Vice President
China Association for Vaccines

姚桐利长期在生物制品行业从事工程技术、企业管理工作。曾任北京生物制品研究所付所长，北京天坛生物制品股份有限公司付总经理、总经理、党委书记。现任中国疫苗行业协会副会长。

Gaoyuan Xu
General Manager
Wuhan Keqian Biology Co.,Ltd.

Xu Gaoyuan, born in 1976, Ph.D., is a professor level senior veterinarian. He is currently the executive deputy general manager and R&D director at Wuhan Keqian Biology Co., Ltd., and concurrently the director of the key laboratory of the Ministry of Agriculture and Rural Affairs for the creation of animal biological preparations, the director of the Hubei Provincial Animal Biological Preparation Engineering Technology Research Center, the vice chairman of the Biological Products Branch of the Chinese Association of Animal Science and Veterinary Medicine, council member of the National Veterinary Drug Industry Technical Innovation Alliance, vice president of Hubei Animal Health Products Association, council member of Hubei Society for Microbiology, and council member of Hubei Pig Industry Association. He has presided over more than 10 projects at the national, provincial and ministerial, and municipal levels; obtained 32 national patents for invention, 1 second prize of National Science and Technology Progress Award, 5 first prizes of Hubei Science and Technology Progress Award, and 4 new veterinary drug registration certificates; and published more than 20 research papers.

莫凡
博士
浙江大学-美国华盛顿大学联合培养博士
资深研究员，加拿大不列颠哥伦比亚大学（UBC）
联合创始人& CEO，杭州纽安津生物科技有限公司
创始人，杭州芯原力生物科技有限公司
兼任研究员，浙江大学药学院

通过人工智能等算法构建肿瘤分型及预后标志物模型、探索肿瘤发生发展及耐药机制、设计新生抗原疫苗并制定个体化的精准诊疗策略；
作为第一作者或通讯作者已在European Urology、Genome Biology、Clinical Cancer Research、JAMA Oncology等国际顶尖杂志发表学术论文30多篇；
参与ICGC (国际癌症基因组联盟) 前列腺癌加拿大组，负责转录组二代测序数据分析；
作为主要负责人获得CIHR、Movember Discovery等多项加拿大全国性科研基金资助

Fengcai Zhu
Deputy director, chief physician, Doctoral supervisor
Jiangsu Provincial Center for Disease Control ande Prevention

Xin Chen
Product Manager
Camfil Filtration (Kunshan) Co., Ltd.
Product manager of Camfil Filtration (Kunshan) Co., Ltd. He has been engaged in air filter and cleanroom industry Since 2012. He is now responsible for particulate product of Camfil China, include air filtration devices from general ventilation and cleanroom application, which used in many different segments.

Chen Xin has participated in a number of high-level biological laboratories, P3 level animal vaccine production workshops, and COVID-19 vaccine plants. And Camfil successfully provide high level air supply and exhaust filtration solutions as per relevant standard.

At the same time, as a company representative, he successively participated in the preparation of standards such as GB/T13554-2020 《High-efficiency Air Filter》 and 《Design Code for Veterinary Drug Clean Room》.

Tian Kegong
Ph.D., researcher
Pulike Biological Engineering, Inc.,

Tian Kegong, male, 1964, Ph.D., researcher, special allowance expert of the State Council, young and middle-aged expert with outstanding contributions to China. He has long been engaged in the research on the etiology, pathogenesis, prevention and control technology and products of important animal diseases. He is now the vice general manager of Pulike Biological Engineering, Inc., the director of the National Research Center for Veterinary Medicine, and concurrently serves as Distinguished Professor of Henan Agricultural University, doctoral supervisor, chief expert of the reference laboratory of porcine reproductive and respiratory syndrome of the world organization for animal health (OIE), the deputy of the 13th National People's Congress.
Researcher Tian Kegong has been working hard for a long time in the front line of animal disease prevention and control, and has made outstanding contributions to the healthy development of animal husbandry in China. He presided over / participated in 41 scientific research projects such as national key R & D plan, isolated and identified 997 strains of 43 kinds pathogens, completed gene sequencing and analysis of 757 strains of 26 kinds of viruses, and created more than 1100 monoclonal antibodies against 24 kinds of pathogens. Aiming at 27 kinds of epidemic diseases in 7 kinds of animals, we have developed and obtained 41 new veterinary drug registration certificates (1 in class I and 10 in class II); and 131 invention patents (23 international patents in 8 countries, such as the United States, Japan, Britain, France and Germany) were authorized; he has published 342 papers (85 included in SCI) and published 7 epidemic prevention and control works (a total of 9.265 million words), participated in 28 works; he led and formulation of 26 standards (16 national standards and 10 industry standards), and the achievements have won more than 20 science and technology awards, including the second-class award of National Science and Technology Progress Award, the China Patent Gold Award, the first-class award of Henan Science and Technology Progress Award, and the first-class award of Shennong China Agricultural Science and Technology Award. The products have been transferred to 68 companies and state-owned enterprises in the industry, with a technology transfer amount of 316 million RMB and a sales revenue of more than 10 billion RMB, which has driven the technological progress and industrial upgrading of China's veterinary drug industry; the products have been popularized and applied nationwide, with more than 15.9 billion heads/share, providing important technical and product support for China's animal disease prevention and control, effectively ensuring the health development of the breeding industry!
In addition, researcher Tian Kegong won the awards and honors include the honorary titles of national outstanding agricultural research talents, national outstanding scientific and technological workers, Henan Zhongyuan scholars and Henan excellent experts, and also served as the vice president of infectious diseases branch of China animal husbandry and Veterinary Society, vice president of public health branch, vice president of small animal medicine branch, vice president of national pig industry technology innovation strategic alliance, and vice president of China animal husbandry and Veterinary Society He is a member of the Veterinary Medicine Dictionary Committee, a member of the national animal epidemic prevention expert committee, and a member of the Chinese society of animal husbandry and veterinary medicine.

Guo Huichen
Supervisor of Ph.D. student, Chief of Foot-and-Mouth Disease Prevention and Control Technology Team, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

Dr. Guo Huichen, Supervisor of Ph.D. student, Chief of Foot-and-Mouth Disease Prevention and Control Technology Team, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. The Chinese academy of agricultural sciences in 2015 "youth talents scheme" class A talented person, the Ministry of Science and Technology in 2016 young and middle-aged leading science and technology innovation talents, in 2017 countries in the third batch of "ten thousand plan", the Chinese academy of agricultural sciences in 2018 "agricultural talents" class B, "chutian scholar program" distinguished professor and the bohai sea - outstanding contribution expert of person of outstanding ability and other honorary titles.

She mainly engages in the research of animal virus pathogenic biology and the interdisciplinary research of virus as nanomaterials. She has established the assembly and optimization technology platform of animal virus-like particles (VLPs), and obtained the first reported foot-and-mouth disease VLPs assembled by prokaryotic expression system in China. The technology and related products have won 15 Chinese invention patents, 3 American patents, 4 biosafety certificates, 4 clinical approval documents. Shen won the 9th Dabeinong Science and Technology Award, Gansu Province Patent First Prize and Gansu Province Patent Inventor Award successively. As the first and corresponding author, more than 70 papers have been published in famous international journals such as Protein and Cell, J Immunol, J Virol, Nanoscale, NanoMedicine: NBM, Cell and Death Diease, RNA Biology, and 2 of them were cover papers of Nanoscale and J Virol. She is the associate editor of book "Natural Molecular Immunology", and co-author of other 5 books. She has presided over 5 national research projects (including 1 project of National key research and development project, 3 projects of the National Natural Science Foundation of China, 2 projects of the introduction of wisdom from the foreign affairs bureau) and more than 10 provincial and ministerial level/institute level scientific research projects.She is a member of Foot and Mouth Disease Branch of Animal Husbandry and Veterinary Society, a member of Biotechnology Branch of Animal Husbandry and Veterinary Society, and a member of Infection and Immunization Branch of Gansu Immunology Society.

Dr. Teng Yigang
Chief scientist of Biopharma product lines

Yeasen Biotech Co. Ltd

Dr. Teng graduated from shanghai institute of Biochemistry and cell biology, CAS. He is the Research manager of Yeasen Biotech Co. Ltd and responses for Enzymes used in vitro transcription.

Dr. Zhaoqing

director of Enterprise Technology Center in Jofunhwa Biotechnology Group Co.,Ltd.

Dr. Zhaoqing He graduated from College of Veterinary Medicine, China Agricultural University (CAU) in 2002, Who had been Sub-project manager under National Key Technologies R&D Program and Project manager under Municipality Science and Technology Program, Council Member of Chinese Association of Animal Science & Veterinary Medicine.
Up to now from 2002, he has about 20 years veterinary vaccine R&D and manufacture experience in Animal Health Companies. At present, he is director of Enterprise Technology Center in Jofunhwa Biotechnology Group Co.,Ltd.. For many years, he has been involved in R&D of veterinary vaccines, approval procedure of veterinary drug products license, manufacture processes and clinical technical service, including lab research, pilot production and process transformation, clinical evaluation of veterinary vaccines, application of new technology in quality evaluation of veterinary vaccines.